“Car-T and Bispecific Antibodies for Refractory Non-Hodgkin Lymphoma: Long-Term Safety and Autoimmune Sequelae”. (2025) Journal of Carcinogenesis, 24(6s), pp. 805–820. doi:10.64149/J.Carcinog.24.6s.805-820.